Acesso livre
Acesso livre

Hematologia Geral

Mais um estudo observacional sugere que rivaroxabam está associado com taxas mais altas de sangramento gastrintestinal do que outros anticoagulantes orais diretos (DOACs).

19 Out, 2021 | 12:44h

Rivaroxaban Is Associated with Higher Rates of Gastrointestinal Bleeding Than Other Direct Oral Anticoagulants: A Nationwide Propensity Score–Weighted Study – Annals of Internal Medicine (link para o resumo – $ para o texto completo)

Comentário: Rivaroxaban Again Linked to More Bleeding vs Other DOACs – TCTMD

Conteúdo relacionado: Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study – Gastroenterology

 

Comentário no Twitter

 

Estudo randomizado embasa o uso de heparina em dose terapêutica para pacientes não críticos internados por Covid-19.

18 Out, 2021 | 08:57h

Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial – The BMJ

Comentário: High-dose of readily available blood thinner reduces risk of death for moderately ill COVID-19 patients – St. Michael’s Hospital

Estudos relacionados (alguns resultados conflitantes)

RCT: Therapeutic-dose heparin superior to standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19.

Another meta-analysis suggests standard-dose prophylactic anticoagulation is the best option for patients hospitalized with Covid-19.

M-A: Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19 – According to this analysis, standard-dose prophylactic anticoagulation should be the standard of care for hospitalized patients with COVID-19 who do not have an indication for therapeutic anticoagulation, irrespective of disease severity.

RCT: In noncritically ill patients hospitalized with Covid-19, therapeutic-dose anticoagulation with heparin increased the probability of survival to hospital discharge compared with usual-care thromboprophylaxis.

RCT: In critically ill patients with Covid-19, therapeutic anticoagulation with heparin did not result in improved outcomes compared to usual-care pharmacologic thromboprophylaxis.

RCT: In patients hospitalized with Covid-19 with elevated D-Dimer, a full-dose anticoagulation strategy based on rivaroxaban (full-dose heparins in unstable patients) + rivaroxaban to day 30 was not better than prophylactic anticoagulation and increased bleeding risk.

 

Comentário no Twitter

 

Diretrizes para anestesiologistas sobre o manejo do sangue do paciente em cirurgia cardíaca.

18 Out, 2021 | 08:46h

2021 Clinical Practice Guidelines for Anesthesiologists on Patient Blood Management in Cardiac Surgery – Journal of Cardiothoracic and Vascular Anesthesia

 

Comentário no Twitter

 

Diretrizes ASH 2021 para transplante de célula-tronco em pacientes com doença falciforme.

14 Out, 2021 | 10:43h

American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation – Blood

Comunicado de imprensa: ASH Releases New Clinical Practice Guidelines on Stem Cell Transplantation in Sickle Cell Disease

Comentário: ASH Issues Guideline on the Use of HSCT for Sickle Cell Disease – HealthDay

Revisão sistemática | Anticoagulantes orais diretos (DOACs) podem ser benéficos para pessoas em tratamento de câncer que não têm indicação terapêutica ou profilática de anticoagulação.

14 Out, 2021 | 10:35h

Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation – Cochrane Library

Prevalência de anemia em mulheres em idade reprodutiva nos países de baixa e média rendas entre 2000 e 2018.

13 Out, 2021 | 13:13h

Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018 – Nature Medicine

Comentário convidado: Anemia in women — an intractable problem that requires innovative solutions – Nature Medicine

Estudo randomizado | Não há benefício da terapia antitrombótica (aspirina ou apixabam) para pacientes ambulatoriais com COVID-19 sintomática clinicamente estáveis.

13 Out, 2021 | 12:56h

Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial – JAMA

Editorial: Antithrombotic Therapy for Outpatients With COVID-19: Implications for Clinical Practice and Future Research – JAMA

 

Comentário no Twitter

 

Teste do D-dímero para excluir embolia pulmonar tem utilidade clínica limitada em pacientes internados com COVID-19 – A maioria dos pacientes, com ou sem embolia pulmonar, apresenta níveis elevados.

13 Out, 2021 | 12:54h

D-Dimer Testing for the Exclusion of Pulmonary Embolism Among Hospitalized Patients With COVID-19 – JAMA Network Open

Comentário: D-Dimer Level Not Useful for Ruling Out PE in COVID-19 Patients – HealthDay

Estudo randomizado | Dose terapêutica de heparina se mostrou superior à dose profilática ou à dose intermediária para tromboprofilaxia em pacientes de alto risco internados com COVID-19.

12 Out, 2021 | 11:22h

Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial – JAMA Internal Medicine

Comentário convidado: Anticoagulant Therapy in Patients Hospitalized With COVID-19 – JAMA Internal Medicine

Estudos relacionados (alguns resultados conflitantes)

Another meta-analysis suggests standard-dose prophylactic anticoagulation is the best option for patients hospitalized with Covid-19.

M-A: Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19 – According to this analysis, standard-dose prophylactic anticoagulation should be the standard of care for hospitalized patients with COVID-19 who do not have an indication for therapeutic anticoagulation, irrespective of disease severity.

RCT: In noncritically ill patients hospitalized with Covid-19, therapeutic-dose anticoagulation with heparin increased the probability of survival to hospital discharge compared with usual-care thromboprophylaxis.

RCT: In critically ill patients with Covid-19, therapeutic anticoagulation with heparin did not result in improved outcomes compared to usual-care pharmacologic thromboprophylaxis.

RCT: In patients hospitalized with Covid-19 with elevated D-Dimer, a full-dose anticoagulation strategy based on rivaroxaban (full-dose heparins in unstable patients) + rivaroxaban to day 30 was not better than prophylactic anticoagulation and increased bleeding risk.

 

Comentário no Twitter

 

Revisão | Inibição da agregação plaquetária após colocação de stent coronariano em pacientes em uso de anticoagulação oral.

8 Out, 2021 | 10:55h

Inhibition of Platelet Aggregation After Coronary Stenting in Patients Receiving Oral Anticoagulation – Deutsches Ärzteblatt International

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.